Reference Interval:
Negative: 0-45% modulating
Positive: 46% or greater modulating
Effective August 20, 2012
|
| Interpretive Data: |
Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.
See Compliance Statement B: www.aruplab.com/CS
|
| CPT Code(s): |
83516
|
Cross References: |
Myasthenia Gravis Antibodies (Acetylcholine Receptor Modulating Antibody) |
|
